House Bill 6478
115th Congress(2017-2018)
Biosimilars Competition Act of 2018
Introduced
Introduced in House on Jul 23, 2018
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
6478
Congress
115
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
No House votes have been held for this bill.
Summary
Biosimilars Competition Act of 2018
This bill amends the Public Health Service Act to require a biologic manufacturer and a biosimilar drug manufacturer to provide notification to the Department of Justice and the Federal Trade Commission regarding certain pharmaceutical agreements. The agreements requiring notice are those related to the manufacturer, marketing or sale of the biosimilar product or the reference product.
Biosimilars are biological products approved by the Food and Drug Administration based on their similarity to an already-approved biological product.
July 23, 2018
07/27/2018
Referred to the Subcommittee on Health.
07/23/2018
Referred to the House Committee on Energy and Commerce.
07/23/2018
Introduced in House
Public Record
Record Updated
Jan 11, 2023 1:41:58 PM